A01

Advanced Cell Engineering (ACE) to Exhibit at Electrochemical Society

Retrieved on: 
Friday, October 7, 2022
ACE, VLF, LFP, High society, Technology, Energy, EVS, Ministry of Education (Malaysia), Learning, Industry, EV, Chemistry, New Approach to Appraisal, A01, Electrochemical Society, Electric battery

STUART, Fla., Oct. 7, 2022 /PRNewswire/ -- Advanced Cell Engineering (ACE), a developer and licensor of advanced lithium-ion battery technologies for the electric vehicle (EV) industry, will be exhibiting at the Electrochemical Society at the Atlanta Hilton on Oct. 9-13 in booth 205. ACE, as the Electrochemical Society's newest institutional member, is establishing itself as an innovative contributor in advanced battery cell technology. Additionally, ACE's Lead Research Scientist, Dr. Mani Manivannan, is organizing the A01 symposium (New Approaches and Advances in Electrochemical Energy Systems) at the conference and sits on the board of the Electrochemical Society.

Key Points: 
  • STUART, Fla., Oct. 7, 2022 /PRNewswire/ -- Advanced Cell Engineering (ACE), a developer and licensor of advanced lithium-ion battery technologies for the electric vehicle (EV) industry, will be exhibiting at the Electrochemical Society at the Atlanta Hilton on Oct. 9-13 in booth 205.
  • ACE, as the Electrochemical Society's newest institutional member, is establishing itself as an innovative contributor in advanced battery cell technology.
  • Additionally, ACE's Lead Research Scientist, Dr. Mani Manivannan, is organizing the A01 symposium (New Approaches and Advances in Electrochemical Energy Systems) at the conference and sits on the board of the Electrochemical Society.
  • Advanced Cell Engineering develops and licenses advanced lithium-ion battery cell technologies for the electric vehicle industry.

Mitsubishi Tanabe Pharma America Presents 48-Week Results from Global Phase 3 Safety Clinical Study of RADICAVA ORS® (edaravone), an Oral Treatment for ALS

Retrieved on: 
Wednesday, June 1, 2022
McGill University Health Centre, Prognosis, Precision medicine, IV, SB, A03, Multimedia, ORS, Mitsubishi Tanabe Pharma, History, Edaravone, Pneumonia, Headache, Diabetic ketoacidosis, Bruise, Breathe Me, Food, Average absolute deviation, Central nervous system, Ageing, Back pain, Solution, Red, BST, MTPA, Failure rate, Suicide, Hypersensitivity, Anaphylaxis, ALS, Prevalence, Dysphagia, SD, Constipation, Death, Erythema multiforme, Facebook, Fatigue, Week, Amyotrophic lateral sclerosis, LinkedIn, Weakness, Feeding disorder, Disease, Policy, FDA, A01, Hives, FRCP, Twitter, Water, Hospital, Safety, Medical device, Pharmaceutical industry, Dietary supplement, Generic drug, Communications satellite, Fine chemical, Patient

JERSEY CITY, N.J., June 1, 2022 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced 48-week results from the global Phase 3 open-label, multi-center clinical trial (MT-1186-A01) assessing the safety and tolerability of RADICAVA ORS® (edaravone) in patients with amyotrophic lateral sclerosis (ALS). Details about the findings will be presented at the European Network to Cure ALS (ENCALS) Meeting 2022, being held in Edinburgh, Scotland, from June 1-3.

Key Points: 
  • "These data reinforce the potential significance of RADICAVA ORS and its important role in the treatment of this devastating disease."
  • Patients should not eat or drink (except water) within one hour after taking RADICAVA ORS.1
    Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc (MTPA).
  • About Mitsubishi Tanabe Pharma America, Inc.
    Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc.
  • MTDA is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's 100 percent-owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. For more information, please visit https://mt-pharma-development-america.com/ .

Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Research at Virtual 32nd International Symposium on ALS/MND

Retrieved on: 
Wednesday, December 1, 2021
ALS, McGill University Health Centre, Central nervous system, Prognosis, B.A, Dizziness, Amyotrophic lateral sclerosis, A03, LinkedIn, MTPA, A01, Facebook, Food, MNDA, Face, Precision medicine, Allergy, Headache, Bruise, Massachusetts General Hospital, Breast milk, Tracheal intubation, Research, Average absolute deviation, Hospital, Patient, Hypersensitivity, Effectiveness, Asthma, Tongue, Vitamin, MBA, Clinical trial, Solution, Motor Neurone Disease Association, Twitter, FRCP, Clinical study design, FDA, Mitsubishi Tanabe Pharma, Multimedia, Itch, Doctor of Pharmacy, Amyotrophy, Program, COVID-19, BCPP, Randomness, Syncope, Wheeze, NGT, Pharmaceutical industry, Generic drug, Palladium, Birth control, Fine chemical

The U.S. Food and Drug Administration (FDA) approved RADICAVA(edaravone) IV on May 5, 2017 as a treatment for amyotrophic lateral sclerosis (ALS).1Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) approved RADICAVA(edaravone) IV on May 5, 2017 as a treatment for amyotrophic lateral sclerosis (ALS).1Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc.
  • About Mitsubishi Tanabe Pharma America, Inc.
    Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc.
  • The U.S. headquarters of Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) is located in Jersey City, New Jersey.
  • MTDA is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's 100 percent-owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTDA is dedicated to research and develop innovative pharmaceutical products that address the unmet medical needs of patients.